- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06952348
Hypertensjonsreduksjon gjennom gangtrapper kontra rask gang (HYPERWALK)
Hypertensjonsreduksjon gjennom gangtrapper kontra rask gange hos individer med økt kardiometabolsk risiko - Hyperwalk randomisert kontrollert studie
This clinical trial investigates whether incorporating stair walking into daily routines improves physical health in adults at risk of lifestyle-related conditions such as hypertension, type 2 diabetes, and cardiovascular disease. Participants will be randomized into three groups: (1) stair walking combined with brisk walking, (2) brisk walking alone, and (3) a control group receiving standard lifestyle advice without specific exercise instructions, stratified by age (<65 y/o, v >=65) and site.
The primary objective is to assess whether the combination of stair and brisk walking leads to greater reductions in systolic blood pressure compared to brisk walking alone or standard care. Secondary outcomes include changes in cardiometabolic risk factors.
Participants in the stair walking group will be instructed to climb ≥250 steps per day (~5.5 minutes/day or ~37.5 minutes/week), or complete an equivalent elevation via inclined slopes, along with ≥75 minutes of brisk walking per week. Those in the brisk walking group will walk ≥150 minutes per week. The control group will receive general lifestyle advice but no tailored physical activity goals or feedback.
Participants in both active groups will aim to double their baseline activity levels. Physical activity will be continuously monitored using wearable devices. The active groups will receive personalized feedback and motivational support throughout the 6-month intervention period.
If effective, this study may offer a simple, scalable, and low-cost intervention model for use in clinical and public health settings, emphasizing personalized goals, remote monitoring, and behavioral support.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Carl Johan Sundberg
- Telefonnummer: 0046852480000
- E-post: carl.j.sundberg@ki.se
Studer Kontakt Backup
- Navn: Pontus Andell, MD, PhD
- E-post: pontus.andell@ki.se
Studiesteder
-
-
-
Stockholm, Sverige
- Rekruttering
- Södersjukhuset
-
Ta kontakt med:
- Raffaele Scorza
- Telefonnummer: 0046812361000
- E-post: raffaele.scorza@ki.se
-
Stockholm, Sverige
- Har ikke rekruttert ennå
- Karolinska Universitetssjukhuset Huddinge
-
Ta kontakt med:
- Helena Wallin
- Telefonnummer: 0046812380000
- E-post: helena.wallin@ki.se
-
Stockholm, Sverige
- Rekruttering
- Liljeholmen Primary Care Center
-
Ta kontakt med:
- Anna Ugarph-Morawski, MD, PhD
- Telefonnummer: +46812367900 0704872194
- E-post: anna.ugarph-morawski@regionstockholm.se
-
Stockholm, Sverige
- Rekruttering
- Boo Primary Care Center
-
Ta kontakt med:
- Linnea Lindgren, MD
- E-post: linnea.lindgren@ki.se
-
Stockholm, Sverige
- Rekruttering
- Södertälje sjukhus
-
Ta kontakt med:
- Giulia Ferrannini
- Telefonnummer: 0046812324000
- E-post: giulia.ferrannini@ki.se
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria
Men and women aged 35 years or older with increased cardiometabolic risk, defined by all of the following:
-
Clinically confirmed hypertension, with or without antihypertensive treatment, as documented in the Electronic Health Record (EHR).
-
Overweight or obesity, defined as BMI between 27 and 40.
-
Physically inactive lifestyle, defined as either:
- Light intensity or inactive category on the Stanford Brief Activity Survey (SBAS), or
- Light intensity or inactive category in the physical activity section of the Swedish National Board of Health and Welfare Lifestyle Questionnaire.
Exclusion Criteria
Medical contraindications to physical activity (based on FYSS 2021, p. 182):
- Severe, symptomatic aortic stenosis
- Acute pulmonary embolism, myocarditis, pericarditis, or systemic infection (e.g., fever, muscle pain, lymphadenopathy)
- Suspected or known aortic dissection
- Severe hypertension (Grade 3: SBP >180 mmHg or DBP >110 mmHg), regardless of symptoms
- Unstable coronary artery disease (including unstable angina, suboptimally treated stable angina, or recent myocardial infarction <8 weeks)
- Symptomatic, uncontrolled arrhythmia
- Symptomatic, uncontrolled heart failure
Other exclusion criteria:
- Implanted pacemaker or ICD
- Pregnancy
- Smartphone incompatibility with Fitrockr© app (iOS <16 or Android OS <10)
- Inability to understand Swedish or English
- Any condition that may interfere with protocol compliance (e.g., severe mental illness or cognitive impairment)
- Inability to walk stairs
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Stair and brisk walking combined
Participants will double their baseline physical activity levels by combining stair walking and brisk walking. The stair walking goal is ≥250 steps per day (equivalent to ~37.5-45 meters elevation or 15 floor levels), totaling ~37.5 minutes per week. In addition, they will complete ≥75 minutes of brisk walking per week. |
See arms. |
|
Eksperimentell: Brisk walking
Participants will double their baseline physical activity levels by engaging in brisk walking only, with a minimum target of >150 minutes per week. |
See arms. |
|
Aktiv komparator: Standard care
Participants will receive general lifestyle advice aligned with current physical activity guidelines but will not be provided with specific exercise instructions, personalized activity targets, or feedback. They will wear the same activity monitor as the intervention groups, but without access to feedback or goal-setting features. |
See arms. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Systolic Blood Pressure (SBP) at 6 months
Tidsramme: 6 months
|
Office systolic blood pressure (SBP) at 6-month follow-up, adjusted for baseline values. SBP is a validated and widely accepted surrogate marker for cardiovascular morbidity and mortality, as well as overall health risk. |
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diastolic Blood Pressure (DBP)
Tidsramme: 6 months
|
Office diastolic blood pressure (DBP) at 6-month follow-up, adjusted for baseline values. DBP is a clinically relevant indicator of cardiovascular risk and contributes to the assessment of overall blood pressure control. |
6 months
|
|
HOMA-index
Tidsramme: 6 months
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 6-month follow-up, adjusted for baseline values. HOMA-IR is a validated surrogate marker of insulin resistance and metabolic risk, commonly used in cardiometabolic research. |
6 months
|
|
HbA1c
Tidsramme: 6 months
|
Hemoglobin A1c (HbA1c) at 6-month follow-up, adjusted for baseline values. HbA1c reflects average blood glucose levels over the preceding 2-3 months and is a standard marker for assessing glycemic control and diabetes risk. |
6 months
|
|
LDL cholesterol
Tidsramme: 6 months
|
Low-Density Lipoprotein (LDL) cholesterol at 6-month follow-up, adjusted for baseline values. LDL cholesterol is a key biomarker for cardiovascular risk and a primary target in lipid-lowering therapies. |
6 months
|
|
Triglycerides
Tidsramme: 6 months
|
Triglycerides (TG) at 6-month follow-up, adjusted for baseline levels. Elevated TG are associated with increased cardiovascular risk and are a core component of the metabolic syndrome. |
6 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Ernæringsforstyrrelser
- Overernæring
- Kroppsvekt
- Patologiske tilstander, tegn og symptomer
- Oppførsel
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Overvektig
- Overvekt
- Hypertensjon
- Kardiovaskulære sykdommer
- Metabolske sykdommer
- Motorisk aktivitet
- Health Services Administration
- Helsevesenets kvalitet, tilgang og evaluering
- Kvalitet på helsehjelpen
- Kvalitetsindikatorer, helsehjelp
- Standard for omsorg
Andre studie-ID-numre
- 2024-05912-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Blood pressure (systolic and diastolic), BMI, sex, age, HOMA-index, HbA1c, Triglycerides, LDL will be shared.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .